Karnataka-based leading healthcare company Sayre Therapeutics has announced an exclusive distribution agreement with Cancer Genetics Inc. (CGI) for the sales and marketing rights of CGI’s proprietary Tissue of Origin (TOO) test in India and South Asia.
“It is very optimistic to see that a large number of physicians have shown acceptance towards this test and agree that it can take things forward in the process of taking guided decisions or changes with regard to the treatment plan of patients with CUP,” said Ravindranath Kunjithai, Head Medical and Regulatory Affairs, Sayre Therapeutics.
TOO is a microarray-based gene expression test that can locate or identify metastatic, poorly differentiated and undifferentiated cancers, among other challenging tumours. Using the TOO test can result in a change in treatment more than 65 per cent of the time.
“This partnership with Sayre Therapeutics is a very important milestone for us to make precision medicine available in high-growth and high-demand markets such as India. We intend on continuing to widen the access to our exclusive branded selection of genomic and biomarker driven tests. Sayre has also established their spread and influence in the oncology sector throughout India,” said Panna Sharma, CEO and President of Cancer Genetics, a major diagnostic products and services provider.
Experts believe that using the TOO test can be extremely helpful in diagnosis of diseases like Cancer of Unknown Primary (CUP) — a common condition in India.
“It is an enigma to specialists and also, an aggressive disease with hostile diagnosis for patients. Mostly, patients with CUP are subjected to a number of tests and uncertainty about the disease and the condition. Using the TOO test can be extremely helpful, in such cases, as it is based on the concept of gene expression profiling,” said Dr Palanki Satya Dattatreya, Senior Consultant and Medical Oncologist, Omega Hospital, Hyderabad.
“With its high specificity and sensitivity, the TOO test can remove ambiguity and also help the patient in gaining a more precise guideline-based therapy, which can result in potentially better survival rates,” Dr Dattatreya added.
The TOO test can even help in reporting the tissue of origin of more than 15 common tumour types including thyroid, breast, non-small cell lung, pancreatic, gastric, colorectal, liver, bladder, kidney, non-Hodgkin’s lymphoma, melanoma, ovarian, sarcoma, testicular germ cell and prostrate tumours.